☆ 4.6 Editorial Material

Won't you come on in? How to favor lymphocyte infiltration in tumors

ONCOIMMUNOLOGY (2012)

期刊

ONCOIMMUNOLOGY

卷 1, 期 6, 页码 986-988

出版社

LANDES BIOSCIENCE

DOI: 10.4161/onci.20213

关键词

tumor; T cells; immunotherapy; cell trafficking; endothelial cells

类别

Oncology Immunology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Abnormal tumor vasculature and endothelial cell anergy limit tumor/T-cell interactions. We have found that NGR-TNF, a tumor vasculature-homing derivative of TNF, selectively activates endothelial cells in neoplastic tissues and induces the release of chemokines that favor tumor infiltration by T cells, thereby enhancing the efficacy of active and adoptive immunotherapy.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity

Khalid W. Kalim, Jun-Qi Yang, Mark Wunderlich, Vishnu Modur, Phuong Nguyen, Yuan Li, Ting Wen, Ashley Kuenzi Davis, Ravinder Verma, Qing Richard Lu, Anil G. Jegga, Yi Zheng, Fukun Guo

Summary: Targeting Cdc42 in Treg cells has shown promising therapeutic potential in cancer immunotherapy, by enhancing antitumor T-cell immunity without triggering autoimmune reactions. This approach involves inducing Treg cell instability through Cdc42 targeting, leading to improved immune responses against tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Antigen-Specific Stimulation and Expansion of CAR-T Cells Using Membrane Vesicles as Target Cell Surrogates

Valeria Ukrainskaya, Yuri Rubtsov, Dmitry Pershin, Nadezhda Podoplelova, Stanislav Terekhov, Igor Yaroshevich, Anstasiia Sokolova, Dmitry Bagrov, Elena Kulakovskaya, Victoria Shipunova, Sergey Deyev, Rustam Ziganshin, Aleksandr Chernov, Georgii Telegin, Eugene Maksimov, Oleg Markov, Anastasiya Oshchepkova, Marina Zenkova, Jia Xie, Hongkai Zhang, Alexander Gabibov, Michael Maschan, Alexey Stepanov, Richard Lerner

Summary: The development of CAR-T therapy has achieved success in the treatment of B cell leukemia, but the expansion of CAR-T cells remains challenging with current protocols. A novel approach using cell-derived membrane vesicles has been proposed, showing greater potential in stimulating, proliferating, and enhancing the functional activity of CAR-T cells.

SMALL (2021)

添加到收藏夹

Article Oncology

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

Jeong A. Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong Cheung

Summary: This study demonstrates that using anti-VEGF antibodies can significantly improve the therapeutic efficacy of T cell immunotherapies by increasing HEVs and promoting the infiltration of cytotoxic CD8(+) TILs.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Oncology

Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

Shujuan Zhou, Fanyan Meng, Shiyao Du, Hanqing Qian, Naiqing Ding, Huizi Sha, Mei Zhu, Xiaoxiao Yu, Lifeng Wang, Baorui Liu, Jia Wei

Summary: The study introduced a novel bifunctional agent, iRGD-anti-CD3, to enhance T cell infiltration, activation, and cytotoxicity against target cancer cells. The modification significantly inhibited tumor growth and prolonged survival in xenograft mouse models, with additional improvement seen when combined with PD-1 blockade. Mechanistic studies revealed the potential of iRGD-anti-CD3 in promoting T cell extravasation through a transport pathway called vesiculovacuolar organelles in the endothelial cytoplasm.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

CD4+T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Jennifer R. Richardson, Anna Schoellhorn, Cecile Gouttefangeas, Juliane Schuhmacher

Summary: CD4+ T cells, bearing the CD4 co-receptor, are a heterogeneous group of T lymphocytes that play a crucial role in the antitumor immune response by directly or indirectly killing tumor cells. Research is increasingly focusing on both CD4+ and CD8+ T cell subsets in cancer immunotherapy approaches.

CANCERS (2021)

添加到收藏夹

Article Oncology

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice

Cangang Zhang, Lei Lei, Xiaofeng Yang, Kaili Ma, Huiqiang Zheng, Yanhong Su, Anjun Jiao, Xin Wang, Haiyan Liu, Yujing Zou, Lin Shi, Xiaobo Zhou, Chenming Sun, Yuzhu Hou, Zhengtao Xiao, Lianjun Zhang, Baojun Zhang

Summary: The study found that old mice have a higher proportion of cytotoxic CD8(+) T cells, naturally occurring Tregs, among other immune cells in their tumors, while young mice have a higher percentage of exhausted CD8(+) T cells, induced Tregs, among others.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction

Patricia Himmels, Thi Thu Thao Nguyen, Maresa Caunt Mitzner, Alfonso Arrazate, Stacey Yeung, Jeremy Burton, Robyn Clark, Klara Totpal, Raj Jesudason, Angela Yang, Margaret Solon, Jeffrey Eastham, Zora Modrusan, Joshua D. Webster, Amy A. Lo, Robert Piskol, Weilan Ye

Summary: Preclinical and clinical studies show that T cell-dependent bispecific antibodies (TDBs) not only kill tumors but also cause systemic changes, leading to adverse events. In this study, the acute responses to TDBs in tumor-bearing mice were characterized in detail. The results reveal rapid and significant accumulation of lymphocytes and activation of endothelial cells (ECs) around large blood vessels in normal organs, particularly the liver. It is suggested that differential responses in normal tissues and tumors may be attributed to organ-specific ECs, and a list of genes selectively upregulated in large liver vessels by TDBs is identified. Furthermore, the study demonstrates that CD9 facilitates the interaction between T cells and ECs through the support of ICAM-1 in response to soluble factors released from TDB-mediated cytotoxic reactions. These findings provide insights into the response of different vascular beds to cancer immunotherapy and may contribute to improving their safety and efficacy.

EMBO REPORTS (2023)

添加到收藏夹

Article Oncology

Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy

Biaolong Deng, Biaolong Yang, Jieqiong Chen, Shuaiwei Wang, Weiqi Zhang, Yixian Guo, Yichao Han, Hecheng Li, Yongjun Dang, Yaqin Yuan, Xueyu Dai, Yuansheng Zang, Yangyang Li, Bin Li

Summary: This study identifies gallic acid as a compound that promotes the instability of T-reg cells, thereby enhancing the efficacy of immune checkpoint blockade (ICB) therapy in cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

TIL-Derived CAR T Cells Improve Immune Cell Infiltration and Survival in the Treatment of CD19-Humanized Mouse Colorectal Cancer

Can Zhu, Yuanyuan Zhao, Jiaheng He, Huan Zhao, Li Ni, Xinyi Cheng, Yida Chen, Liqian Mu, Xiaojun Zhou, Qin Shi, Jie Sun

Summary: The lack of a tumor-specific antigen as the target and an inhospitable tumor environment limit the clinical application of CAR T in solid tumors. TIL CAR-T cells, which combine the advantages of TIL and CAR T, show superior anti-tumor activity and have advantages in tumor invasion, relieving T cell exhaustion, and promoting immune memory compared to conventional CAR T.

CANCERS (2023)

添加到收藏夹

Article Oncology

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor

Ge Gao, Weiting Liao, Pei Shu, Qizhi Ma, Xia He, Benxia Zhang, Diyuan Qin, Yongsheng Wang

Summary: This study identified the association of S1PR3 high expression with T-cell exhaustion and immunotherapy resistance, and explored the potential of combining S1PR3 antagonist with CAR-T cell therapy, achieving significant efficacy in mouse models of breast cancer and colon cancer. These findings provide a rationale for the combination of S1PR3 inhibitor and CAR-T cells in the treatment of solid tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Immunology

Expression Regulation and Function of T-Bet in NK Cells

Chen Huang, Jiacheng Bi

Summary: T-bet is a critical transcription factor that regulates the development, maturation, and function of NK cells, playing a role in immune surveillance and defense against infections, inflammation, autoimmune diseases, and tumors.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy

Wenyue Zhang, Xiaodi Liu, Shuwen Cao, Qi Zhang, Xiaojiang Chen, Wanrong Luo, Jiabao Tan, Xiaolin Xu, Jing Tian, Phei Er Saw, Baoming Luo

Summary: By simultaneously altering the polarization of tumor-associated macrophages and regulating T cell function, a multifunctional nanoplatform was designed to maximize the efficacy of cancer immunotherapy.

ACS NANO (2023)

添加到收藏夹

Review Immunology

CD8+ T Cell Exhaustion in Cancer

Joseph S. Dolina, Natalija Van Braeckel-Budimir, Graham D. Thomas, Shahram Salek-Ardakani

Summary: Recent research has revealed the heterogeneity within the exhausted CD8(+) T cell lineage, which consists of multiple interconnected subpopulations with distinct characteristics and locations. This understanding calls for a re-focusing of cancer immunotherapies on targeting the driver mechanisms underlying CD8(+) T(ex) development to stabilize functional subsets.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Immunology

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Milad Ahmadi Najafabadi, Fatemeh Yousefi, Seyed Mohamad Javad Mirarefin, Fatemeh Rahbarizadeh

Summary: CAR-T cells have revolutionized cancer treatment for hematologic malignancies, but face challenges in solid tumors due to heterogeneous antigen expression and immunosuppressive tumor microenvironments. Strategies such as boosting vaccines and novel implementations are explored to enhance CAR-T tumoricidal capacity and trigger endogenous antitumor responses.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Addressing TumorHeterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines

Yoshinaga Ito, Deng Pan, Wubing Zhang, Xixi Zhang, Tiffany Y. Juan, Jason W. Pyrdol, Oleksandr Kyrysyuk, John G. Doench, X. Shirley Liu, Kai W. Wucherpfennig

Summary: Tumor heterogeneity is a major obstacle in cancer therapy, including immunotherapy. By targeting autophagy and TNF signaling pathways, MHC-I-deficient tumor cells can be sensitized to T cell-mediated apoptosis. Antigens from apoptotic MHC-I-deficient tumor cells can be efficiently cross-presented by dendritic cells, leading to increased infiltration of T cells producing IFN-γ and TNF-α. Targeting both pathways enables T cell-mediated elimination of tumors with a substantial population of resistant, MHC-I-deficient cells.

CANCER DISCOVERY (2023)

添加到收藏夹

Editorial Material Oncology

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy

Matteo Bellone, Arianna Brevi, Stefania Bruzzi, Michela Consonni, Francesca De Santis, Giulia Di Lullo, Maria Teresa Majorini, Anna Pasto, Alberto Amadori, Marco Bregni, Massimo Di Nicola, Luana Calabro, Pier Francesco Ferrucci, Enrico Proietti, Mario Paolo Colombo, Vincenzo Russo

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

Abdullah Alajati, Mariantonietta D'Ambrosio, Martina Troiani, Simone Mosole, Laura Pellegrini, Jingjing Chen, Ajinkya Revandkar, Marco Bolis, Jean-Philippe Theurillat, Ilaria Guccini, Marco Losa, Arianna Calcinotto, Gaston De Bernardis, Emiliano Pasquini, Rocco D'Antuono, Adam Sharp, Ines Figueiredo, Daniel Nava Rodrigues, Jonathan Welti, Veronica Gil, Wei Yuan, Tatjana Vlajnic, Lukas Bubendorf, Giovanna Chiorino, Letizia Gnetti, Veronica Torrano, Arkaitz Carracedo, Laura Camplese, Susumu Hirabayashi, Elena Canato, Gianfranco Pasut, Monica Montopoli, Jan Hendrik Ruschoff, Peter Wild, Holger Moch, Johann De Bono, Andrea Alimonti

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Editorial Material Genetics & Heredity

ACE polymorphisms and COVID-19-related mortality in Europe

Matteo Bellone, Stefania Laura Calvisi

JOURNAL OF MOLECULAR MEDICINE-JMM (2020)

添加到收藏夹

Letter Oncology

Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy

M. Montopoli, M. Zorziy, V. Cocetta, T. Prayer-Galetti, S. Guzzinati, E. Bovo, M. Rugge, A. Calcinotto

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Breaching the Blood-Brain Tumor Barrier for Tumor Therapy

Fabrizio Marcucci, Angelo Corti, Andres J. M. Ferreri

Summary: The blood-brain tumor barrier (BBTB) is a major obstacle for delivering anticancer drugs to central nervous system tumors. Recent advances in various conjugates and drug delivery technologies have shown promising results in breaching the BBTB and increasing drug delivery to brain tumors, without significant adverse events.

CANCERS (2021)

添加到收藏夹

Article Hematology

CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism

Matteo Grioni, Arianna Brevi, Elena Cattaneo, Alessandra Rovida, Jessica Bordini, Maria Teresa Sabrina Bertilaccio, Maurilio Ponzoni, Giulia Casorati, Paolo Dellabona, Paolo Ghia, Matteo Bellone, Arianna Calcinotto

Summary: The presence of CD4(+) T cells is essential for the development of chronic lymphocytic leukemia (CLL), while CD8(+) T cells have an antitumor effect in restraining CLL progression. Antigen specificity of CD4(+) T cells has marginal impact on CLL development.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfo, Anastasios Stathis, Georg Stussi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Summary: Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity with different subgroups characterized by genetic abnormalities, pathway signatures, and microenvironment compositions. These findings provide insights into the classification and treatment of SMZL.

BLOOD (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

Nicolo Pernigoni, Elena Zagato, Arianna Calcinotto, Martina Troiani, Ricardo Pereira Mestre, Bianca Cali, Giuseppe Attanasio, Jacopo Troisi, Mirko Minini, Simone Mosole, Ajinkya Revandkar, Emiliano Pasquini, Angela Rita Elia, Daniela Bossi, Andrea Rinaldi, Pasquale Rescigno, Penny Flohr, Joanne Hunt, Antje Neeb, Lorenzo Buroni, Christina Guo, Jonathan Welti, Matteo Ferrari, Matteo Grioni, Josee Gauthier, Raad Z. Gharaibeh, Anna Palmisano, Gladys Martinetti Lucchini, Eugenia D'Antonio, Sara Merler, Marco Bolis, Fabio Grassi, Antonio Esposito, Matteo Bellone, Alberto Briganti, Maria Rescigno, Jean-Philippe Theurillat, Christian Jobin, Silke Gillessen, Johann de Bono, Andrea Alimonti

Summary: The gut microbiota enriched for species capable of converting androgen precursors into active androgens was found to contribute to the onset of castration resistance in CRPC. Ablation of the gut microbiota by antibiotic therapy delayed the emergence of castration resistance in mice. Fecal microbiota transplantation from CRPC patients rendered mice resistant to castration.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression

Marco Bolis, Daniela Bossi, Arianna Vallerga, Valentina Ceserani, Manuela Cavalli, Daniela Impellizzieri, Laura Di Rito, Eugenio Zoni, Simone Mosole, Angela Rita Elia, Andrea Rinaldi, Ricardo Pereira Mestre, Eugenia D'Antonio, Matteo Ferrari, Flavio Stoffel, Fernando Jermini, Silke Gillessen, Lukas Bubendorf, Peter Schraml, Arianna Calcinotto, Eva Corey, Holger Moch, Martin Spahn, George Thalmann, Marianna Kruithof-de Julio, Mark A. Rubin, Jean-Philippe P. Theurillat

Summary: The study integrates a transcriptomics atlas of prostate cancer and validates it with preclinical models and single-cell RNA-seq, revealing the role of EZH2 and macrophage polarization in tumour progression.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study

Manuel Zorzi, Stefano Guzzinati, Francesco Avossa, Ugo Fedeli, Arianna Calcinotto, Massimo Rugge

Summary: This study found that the risk of SARS-CoV-2 infection in cancer patients is associated with age, disease activity, tumor type, and resource utilization levels. For infected patients, the risk of death is related to gender, comorbidities, age, and tumor type.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α

Angelo Corti, Teresa Calimeri, Flavio Curnis, Andres J. M. Ferreri

Summary: The blood-brain tumor barrier is a major obstacle for the delivery of anticancer drugs to brain tumors. This review focuses on the development of a drug called NGR-TNF that can target and alter the blood-brain tumor barrier. Preclinical studies have shown that NGR-TNF is a promising strategy for delivering TNF to tumor vessels and breaking the biological barriers. Clinical studies have also demonstrated the efficacy of NGR-TNF in improving patient survival. In addition, the review discusses the challenges and potential solutions for the instability and molecular heterogeneity of NGR-TNF, as well as other peptide/antibody-TNF fusion products and nanoparticles for targeting the blood-brain tumor barrier.

PHARMACEUTICS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care

Francis Schneider, Raphael Clere-Jehl, Francesco Scavello, Thierry Lavigne, Angelo Corti, Tommaso Angelone, Youssef Haikel, Philippe Lavalle

Summary: CGA may serve as a biomarker in critically ill patients, associated with short-term death, systemic inflammation, and multiple organ failure; Vasostatin-I, when associated with age and lactate, could be an early prognostic indicator; Catestatin impacts immunity-related proteins and helps fight infections.

PHARMACEUTICS (2022)

添加到收藏夹

Article Oncology

Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer

Nicolo Bancaro, Bianca Cali, Martina Troiani, Angela Rita Elia, Rydell Alvarez Arzola, Giuseppe Attanasio, Ping Lai, Mateus Crespo, Bora Gurel, Rita Pereira, Christina Guo, Simone Mosole, Daniela Brina, Mariantonietta D'Ambrosio, Emiliano Pasquini, Clarissa Spataro, Elena Zagato, Andrea Rinaldi, Mattia Pedotti, Simona Di Lascio, Francesco Meani, Monica Montopoli, Matteo Ferrari, Andrea Gallina, Luca Varani, Ricardo Pereira Mestre, Marco Bolis, Silke Gillessen Sommer, Johann de Bono, Arianna Calcinotto, Andrea Alimonti

Summary: Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. We have identified a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment. These senescent-like neutrophils express TREM2 and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils.

CANCER CELL (2023)

添加到收藏夹

Article Medicine, General & Internal

Role of myeloid-derived suppressor cells in hormone-dependent cancers

Mukherjee Siddhartha, Elia R. Angela, Calcinotto Arianna

Summary: Tumour-infiltrating myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that display immunosuppressive activity in tumor patients, especially in hormone-driven tumors. Recruitment of MDSCs in prostate cancer has been shown to confer resistance to traditional endocrine therapies.

SWISS MEDICAL WEEKLY (2021)

添加到收藏夹

Article Urology & Nephrology

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

Florent Petitprez, Nicola Fossati, Yann Vano, Massimo Freschi, Etienne Becht, Roberta Luciano, Julien Calderaro, Tiffany Guedet, Laetitia Lacroix, Paola M. V. Rancoita, Francesco Montorsi, Wolf Herman Fridman, Catherine Sautes-Fridman, Alberto Briganti, Claudio Doglioni, Matteo Bellone

EUROPEAN UROLOGY FOCUS (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.